[Clinical results of a double blind study with the new antirheumatic agent acemetacin (author's transl)].
In a controlled double blind study the therapeutic efficacy of equimolar doses of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetoxy] acetic acid (acemetacin, TV 1322, Rantudil¿) and indometacin was compared in 32 male and 32 female patients suffering from arthrosis deformans of the large joints or vertebral syndromes. No significant differences were observed between the two substances with regard to the therapeutic efficacy and in the clinical laboratory data. Side effects occurred less frequently under acemetacin than under indometacin; in particular no gastro-intestinal complaints were observed under acemetacin.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D007213:Indomethacin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D007210:Indoleacetic Acids; C026784:acemetacin; D007213:Indomethacin
Klinische Ergebnisse einer Doppelblindstudie mit dem neuen Antirheumatikum Acemetcin.